OncoTherapy Science (TSE:4564) EBIT: 円-907.2 Mil (TTM As of Mar. 2026)

OncoTherapy Science  (TSE:4564) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OncoTherapy Science's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

where

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

OncoTherapy Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OncoTherapy Science's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science EBIT Related Terms

The historical data trend for OncoTherapy Science's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science EBIT Chart

OncoTherapy Science Annual Data
	Trend	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24	Mar25	Mar26
EBIT		Get a 7-Day Free Trial					-2,052.64	-1,116.42	-1,285.50	-811.92	-907.17

OncoTherapy Science Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
EBIT	Get a 7-Day Free Trial															-576.06	-544.07	-267.85	-553.40	-353.77

TSE:4564 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, OncoTherapy Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoTherapy Science EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's EV-to-EBIT falls into.

OncoTherapy Science EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-907.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Business Description